>R&D >R&D in Takeda

R&D in Takeda

Takeda determines its R&D strategy based on the latest medical needs. By concentrating investment of management resources in the core therapeutic areas of Oncology, Gastrointestinal, Central Nervous System, Specialty Cardiovascular and Vaccines, Takeda strives to achieve leading innovation in medicine.


R&D News

Latest Publications of Takeda Research Laboratories

R&D At a Glance

Main R&D Facilities

Takeda Pharmaceuticals International, Inc. (Deerfield, U.S.)

Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. ( São Jerônimo, Brazil)

Takeda Pharmaceuticals International Co. (Cambridge, MA, U.S.)

Takeda California, Inc. (San Diego, CA, U.S.)

Takeda Vaccines, Inc. (Bozeman, MT, U.S.)

Takeda Development Center Americas, Inc. (Deerfield, IL. U.S.)

Takeda Ventures, Inc. (Palo Alto, CA, U.S.)

Takeda GmbH (Konstanz, Germany)

Takeda Cambridge Limited (Cambridge, U.K.)

Takeda Development Centre Europe Ltd. (London, U.K.)
Takeda (China) Holdings Co., Ltd. (Shanghai, China)
Guangdong Techpool Bio-Pharma Co., Ltd. (Guangzhou, China) 
Takeda Singapore Pte Limited (Singapore)

Takeda Development Center Asia, Pte. Ltd. (Singapore)

Takeda Vaccines Pte. Ltd. (Singapore)

Shonan Research Center (Fujisawa, Japan)
Takeda Development Center Japan(Osaka, Japan)
CMC Center (Osaka, Japan)

R&D Investment ¥345.9 billion (FY2015)
Core Therapeutic Areas


Central Nervous System
Specialty Cardiovascular

R&D Pipeline Takeda discloses ethical drugs under development that have reached phase I or higher status